US Army Splashes The Cash On Valneva's JE Vaccine
Executive Summary
Valneva’s 2019 guidance has been boosted by the US Army’s Ixiaro vaccine order, as other products flourish in the pipeline.
You may also be interested in...
Lyme Disease Vaccine Pushes Valneva To US Listing
Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.
Valneva/Emergent BioSolutions' Candidate Zika Vaccine Shows Early Clinical Promise
A European/US company collaboration has reported encouraging safety and immunogenicity in early clinical studies with an alum-adjuvanted Zika vaccine based on inactivated whole virus.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.